• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Novartis

Novartis

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. United Arab Emirates Healthcare, Regulatory and Reimbursement Landscape Report 2016 Featuring ulphar, Neopharma, Pfizer, GlaxoSmithKline & Novartis - Research and Markets

    United Arab Emirates Healthcare, Regulatory and Reimbursement Landscape Report 2016 Featuring ulphar, Neopharma, Pfizer, GlaxoSmithKline & Novartis - Research and Markets

  2. Mallinckrodt to Pay $100 Million to Settle Antitrust Allegations on Unlawful Drug Monopoly -- Update

    Mallinckrodt to Pay $100 Million to Settle Antitrust Allegations on Unlawful Drug Monopoly -- Update

  3. Drug Delivery Technology Market by Route of Administration & Patient Care Setting - Global Forecast to 2021 - Research and Markets

    Drug Delivery Technology Market by Route of Administration & Patient Care Setting - Global Forecast to 2021 - Research and Markets

  4. Former Novartis Pharma-Unit Head Joins Venture-Capital Firm

    Former Novartis Pharma-Unit Head Joins Venture-Capital Firm

  5. UPDATE: Drug makers, auto stocks yank European stocks lower for first time in 3 days

    UPDATE: Drug makers, auto stocks yank European stocks lower for first time in 3 days

  6. Drug and Gene Delivery Devices Market Analysis 2014 - 2025 - Research and Markets

    Drug and Gene Delivery Devices Market Analysis 2014 - 2025 - Research and Markets

  7. Global Multiple Myeloma Drugs Market 2017-2021: Market Growth at 9.19% - Emergence of Nanomedicine Platform - Research and Markets

    Global Multiple Myeloma Drugs Market 2017-2021: Market Growth at 9.19% - Emergence of Nanomedicine Platform - Research and Markets

  8. UPDATE: Drugmakers, retailers yank European stocks from 1-year high

    UPDATE: Drugmakers, retailers yank European stocks from 1-year high

  9. EUROPE MARKETS: Drugmakers, Retailers Yank European Stocks From 1-year High

    EUROPE MARKETS: Drugmakers, Retailers Yank European Stocks From 1-year High

  10. $85.4 Billion Monoclonal Antibodies (mAbs) Market Analysis By Source, By Type of Production, By Indication, By End-use And Segment Forecasts, 2013 - 2024 - Research and Markets

    $85.4 Billion Monoclonal Antibodies (mAbs) Market Analysis By Source, By Type of Production, By Indication, By End-use And Segment Forecasts, 2013 - 2024 - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.